Hikma Pharmaceuticals PLC (HKMPF PINK) stock market data APIs
$22.239
0(0%)
as of August 7, 2026
Try our APIs with
free plan!
Hikma Pharmaceuticals PLC Financial Data Overview
Price chart is built with
Anychart
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and other generic and specialty products for the retail market. It provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company also offers its products in solid, semi-solid, liquid, and injectable dosage forms. It operates in the United Kingdom, Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, United Kingdom.
Prev. Close
22.239
Open
22.239
High
22.239
Low
22.239
52 wk Range
15.9055-24.6625
Market Cap
4 629 M
P/E Ratio
12.6577
Shares Outstanding
208 M
Revenue
3 419 M
Dividends (Yield)
0.0386
Beta
0.66
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at €19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only €19.99
TRY NOW
Get Hikma Pharmaceuticals PLC data using free add-ons & libraries
Get Hikma Pharmaceuticals PLC Fundamental Data
Hikma Pharmaceuticals PLC Fundamental data includes:
- Net Revenue: 3 419 M
- EBITDA: 879 M
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
€
59.99
/mo.
End-of-day & Earnings data
Get Hikma Pharmaceuticals PLC Earnings data
Corporate Events Calendar & News package for
€
19.99
/mo.
What’s included:
- Latest Release: 2026-08-06
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Hikma Pharmaceuticals PLC News
New
Citi sees Hikma discount as unwarranted after upgrade to forecasts
Citi sees Hikma discount as unwarranted after upgrade to forecasts Proactive uses images sourced from Shutterstock Citi has raised its estimates for Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) fol...
Hikma jumps 10% as brokers point to profit beat and undemanding rating
Hikma jumps 10% as brokers point to profit beat and undemanding rating Proactive uses images sourced from Shutterstock Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) shares rose 10% to 1,721p after f...
Citi starts Hikma at 'buy' with strategy reset offering compelling entry point
Citi starts Hikma at 'buy' with strategy reset offering compelling entry point Proactive uses images sourced from Shutterstock Citi has initiated coverage of Hikma Pharmaceuticals PLC (LSE:HIK, OTC:H...
![[Latest] Global Generic Drug Market Size/Share Worth USD 926.54 Billion by 2034 at a 6.55% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)](/build/assets/fallback8-BF3dn4ia.jpg)
[Latest] Global Generic Drug Market Size/Share Worth USD 926.54 Billion by 2034 at a 6.55% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Generic Drug Market size & share revenue was ...
Get Hikma Pharmaceuticals PLC fresh news feed via Financial News API
Corporate Events Calendar & News package for
€19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only €19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
€99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
